Download PDF
Drug Res (Stuttg) 2014; 64(02): 79-84
DOI: 10.1055/s-0033-1353160
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Development of Health Supplement Probiotic in Relation to Physical Strength and Biological Activity in Experimental Animal

P. G. Mahajan
1   Department of Pharmacology, P. Wadhwani College of Pharmacy, Maharashtra, India
,
A. S. Tripathi
1   Department of Pharmacology, P. Wadhwani College of Pharmacy, Maharashtra, India
,
A. V. Chandewar
2   Department of Pharmaceutical chemistry, P. Wadhwani College of Pharmacy, Maharashtra, India
,
K. G. Apte
3   APT Research Foundation, National Toxicology Center, Maharashtra, India
,
P. M. Mazumder
4   Department of Pharmaceutical Sciences, Birla Institute of Technology, Jharkhand, India
,
G. D. Mahajan
5   Department of ENT, Padmashri Dr. D.Y. Patil Medical College, Maharashtra, India
› Author Affiliations
Further Information

Publication History

received 11 February 2013

accepted 12 July 2013

Publication Date:
28 August 2013 (online)

Also available at
    Permissions and Reprints

Abstract

A probiotic nutritive health supplement having a healthy nutritive value was formulated to enhance body function. A 90 days study proved the formulated health supplement to improve the body weight with a maintained normal level of cholesterol and triglycerides in blood which is needful for the proper cardiac function. The supplement also maintained the blood parameters to avoid any illness in the body. In the present study, the health supplement was able to maintain the Haemoglobin level, RBC Count, WBC Count, Platelet Count in Sprague Dawley rats. It is also found that the supplement maintained the cardiac rhythm in the stressful condition and increased in the time of swimming in the force swimming test which indicates an increase in the physical strength.

Key words

probiotics - cardiac function - haemoglobin - force swimming test
 

  • References

  • 1 Guarner F, Perdigon G, Coerthier G et al. Should Yogurt cultures be considered Probiotic. British Journal Nutrition 2005; 93: 783-786
    CrossrefPubMedGoogle Scholar
  • 2 Guidelines for the evaluation of probiotics in food: Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food, London, Ontario, Canada. 2002. Available at: http://www.fermentedfoods.net/wgreport2.pdf Accessed 19 December 2007
    PubMed
  • 3 Cherayil BJ, Walker WA. Ontogeny of the host response to enteric microbial infection. In: Hecht G. ed. Microbial pathogenesis and the intestinal epithelial cell. Washington, DC: ASM Press; 2003: 333-349
    CrossrefGoogle Scholar
  • 4 Kerneis S, Bogdanova A, Kraehenbuhl JP et al. Conversion by Peyer’s patch lymphocytes of human enterocytes into M cells that transport bacteria. Science 1997; 277: 910-911
    CrossrefPubMedGoogle Scholar
  • 5 Kohler H, McCormick BA, Walker WA. Bacterial enterocyte cross talk Cellular mechanisms in health and disease. Journal Paediatrics Gastroenterology of Nutrition 2003; 36: 175-185
    PubMedGoogle Scholar
  • 6 Macpherson AJ, Lamarre A, McCoy K et al. IgA production without µ (mu) or δ (delta) chain expression in developing B cells. Natural Immunology 2001; 2: 625-631
    PubMedGoogle Scholar
  • 7 Rescigno M, Urbano M, Valzasina B et al. Ricciardi- Castagnoli Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Natural Immunology 2001; 2: 361-367
    PubMedGoogle Scholar
  • 8 Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004; 303: 1662-1665
    CrossrefPubMedGoogle Scholar
  • 9 Rachmilewitz D, Katakura K, Karmeli F et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126: 520-528
    CrossrefPubMedGoogle Scholar
  • 10 Neish Andrew S, Gewirtz Andrew T, Zeng Hui et al. Prokaryotic regulation of epithelial responses by inhibition of IkBα degradation. Science 2000; 289: 1560-1563
    CrossrefPubMedGoogle Scholar
  • 11 Otte JM, Podolsky DK. Functional modulation of enterocytes by gram positive and gram negative microorganisms. American Journal of Physiology and Gastrointestineology Liver Physiology 2004; 286: G613-G626
    PubMedGoogle Scholar
  • 12 Kalliomaki MA, Walker WA. Physiologic and pathologic interactions of bacteria with gastrointestinal epithelium. Gastroenterology Clinical North American Journal 2005; 34: 383-399
    PubMedGoogle Scholar
  • 13 Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. Journal of American Microbiological Association 1996; 275: 870-876
    PubMedGoogle Scholar
  • 14 Eschenbach DA, Davick PR, Williams BL et al. Prevalence of hydrogen peroxide producing Lactobacillus species in normal women and women with bacterial vaginosis. Journal Clinical Microbiology 1989; 27: 251-256
    PubMedGoogle Scholar
  • 15 Klebanoff SJ, Coombs RW. Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. Journal Experimental Medicine 1991; 174: 289 -292
    CrossrefPubMedGoogle Scholar
  • 16 Reid G. Probiotic agents to protect the urogenital tract against infection. American Journal Clinical Nutrition 2001; 73: 437S-443S
    PubMedGoogle Scholar
  • 17 Meydani S, Ha WK. Immunologic effects of yogurt. American Journal of Clinical Nutrition 2000; 71: 861-872
    PubMedGoogle Scholar
  • 18 Van de Water J, Keen CL, Gershwin ME. The influence of chronic yogurt consumption on immunity. Journal of Nutrition 1999; 129: 1492S-1425S
    PubMedGoogle Scholar
  • 19 Anderson JW, Gilliland SE. Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. Journal American Collection of Nutrition 1999; 18: 43-50
    PubMedGoogle Scholar
  • 20 Hove H, Norgaard H, Mortensen PB. Lactic acid bacteria and the human gastrointestinal tract. European Journal Clinical Nutrition 1999; 53: 339-350
    PubMedGoogle Scholar
  • 21 Kalliomki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet 2001; 357: 1076-1079
    CrossrefPubMedGoogle Scholar
  • 22 Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. Journal Allergy Clinical Immunology 1997; 99: 179-185
    PubMedGoogle Scholar
  • 23 Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. International Journal of Antimicrobial Agents October 2003; 22: 360-366
    CrossrefPubMedGoogle Scholar
  • 24 Bravo JA, Forsythe P, Chew MV et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences 2011; 108: 16050-16055
    CrossrefPubMedGoogle Scholar
  • 25 Metchnikoff E. Études sur la flore intestinale. Ann Inst Pasteur Paris 1908; 22: 929-955
    PubMedGoogle Scholar
  • 26 Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633
    CrossrefPubMedGoogle Scholar
  • 27 Sartor RB. Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. In Kirsner’s inflammatory bowel diseases. eds. Sartor RB, Sandbom WJ. Edinburgh: Elsevier; 2003: 138-162
    Google Scholar
  • 28 Chu FF, Esworthy RS, Chu PG et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res 2004; 64: 962-968
    CrossrefPubMedGoogle Scholar
  • 29 Kim DH, Jin YH. Intestinal bacterial beta-glucuronidase activity of patients with colon cancer. Arch Pharm Res 2001; 24: 564-567
    CrossrefPubMedGoogle Scholar
  • 30 Morotomi M, Kado S. Intestinal microflora and cancer prevention. Gan To Kagaku Ryoho 2003; 30: 741-747
    PubMedGoogle Scholar
  • 31 Balsari A, Ceccarelli A, Dubini F et al. The fecal microbial population in the irritable bowel syndrome. Microbiology 1982; 5: 185-194
    PubMedGoogle Scholar
  • 32 King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 1187-1189
    CrossrefPubMedGoogle Scholar
  • 33 Watanabe S, Narisawa Y, Arase S et al. Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J Allergy Clin Immunol 2003; 111: 587-591
    CrossrefPubMedGoogle Scholar
  • 34 Pothoulakis C, Kelly CP, Joshi MA et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104: 1108-1115
    PubMedGoogle Scholar